Vertex Broadens Beyond Cystic Fibrosis As CASGEVY And Pipeline Take Shape

Vertex Pharmaceuticals (NasdaqGS:VRTX) reported strong Q4 results, reflecting continued execution on its broader portfolio ...
FierceBiotech

Vertex, beaten by rare disease again, drops 2 assets on growing discard pile

Vertex’s attempt to treat a rare genetic disease has hit another setback. The biotech tossed two more drug candidates onto the discard pile in response to underwhelming data but, following a playbook ...

Vertex Partners With WuXi To Broaden Autoimmune Pipeline Beyond Cystic Fibrosis

Vertex Pharmaceuticals (NasdaqGS:VRTX) entered an agreement with WuXi Biologics to co-develop a trispecific T-cell Engager for B-cell mediated autoimmune diseases. The collaboration focuses on ...

Vertex Report: U.S. Sees Record-Level Growth in Sales Tax Rates and Rules Changes in 2025 Amid Fiscal Uncertainty

(NASDAQ:VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today released its 2025 End‑of‑Year U.S. Sales Tax Rates and Rules Report. Tracking 12,414 U.S. tax ...
The Motley Fool

Vertex Pharmaceuticals Will Use $100 Million to Tank Its Own Market Share. Here's Why That's a Smart Move.

Vertex Pharmaceuticals will soon try to commercialize another medicine. The new therapy targets the same market as four of its other products. Using a priority review voucher is an expensive choice, ...

Should you buy Vertex before Feb. 12?

Biotech Vertex, known for its cystic fibrosis therapies, is set to report earnings on Feb. 12 ...
The Boston Globe

Vertex falls after FDA doubts broad use of chronic pain drug

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators said they didn’t see a path forward for broad use of its pill in treating a ...
MedCity News

Vertex Pharma’s Opioid Alternative Wins FDA Approval, First in a New Class of Pain Meds

A novel Vertex Pharmaceuticals drug that takes a new approach to pain is now approved by the FDA, a landmark decision for a first-in-class product that brings patients a treatment alternative intended ...

Vertex, Inc. (NASDAQ: VERX) Q4 2025 earnings call transcript

Vertex, Inc. (NASDAQ:VERX) Q4 2025 Earnings Call Transcript February 11, 2026 Vertex, Inc. misses on earnings expectations. Reported EPS is $ EPS, expectations were $0.17. Operator: Good day, and ...
Seeking Alpha

Vertex And CRISPR Therapeutics - Partners On Exa-cel - But Unequally Valued

Switzerland-based CRISPR Therapeutics (CRSP) and Boston, Massachusetts-based Vertex (VRTX) have been collaborating together since signing an initial agreement in 2015, with Vertex paying CRISPR $75m ...
Business Wire

Vertex and Arbor Biotechnologies Establish Collaboration to Discover Novel Proteins to Advance Discovery of Gene-Editing Therapies

BOSTON & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Arbor Biotechnologies (Arbor) today announced that the two companies have entered into a strategic ...